CTSO CytoSorbents Corporation Total Debt to Capital

Cytosorbents (CTSO) leads the development of blood purification technologies for intensive care units, utilizing filters to combat sepsis. The business is in a defensive phase, as demographics and medical needs make it resilient to macroeconomic crises. This daily price action, visualized for analytical convenience, reflects a debt-to-equity ratio of 0.00, while the company faces physician conservatism and pressure from traditional dialysis systems.

This ratio compares total liabilities to equity, determining the degree of financial leverage and the company's dependence on borrowed funds. By analyzing the current total debt-to-equity ratio on GURU.Markets, an investor assesses the stability of Cytosorbents (CTSO), whose monopoly position in the cytokine blood purification segment allows it to effectively balance its debt load while scaling the unique CytoSorb technology.